Autres langues Longeveron Inc.

Actions

LGVN

US54303L2034

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 02/05/2024			Varia. 5j.	Varia. 1 janv.
1,81 ^USD	+4,02%		+8,38%	-86,69%

08/04	Les plus fortes hausses du prémarché	MT
20/03	Longeveron procède à un regroupement d'actions à raison de 1 pour 10	MT

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Longeveron to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024	14:03
Longeveron Files Prospectus for Secondary Offering	30/04
Longeveron to Present at the Planet MicroCap Showcase	25/04
Longeveron Raises a Total of $11.4 Million in Gross Proceeds from Warrant Exercise Offering and Public Offering	18/04
Longeveron Announces Exercise of Warrants for $6.2 Million Gross Proceeds	17/04
Longeveron's CLEAR MIND Randomized Phase 2a Clinical Trial Evaluating Lomecel-B in Mild Alzheimer's Disease Accepted for Featured Research Session Oral Presentation	16/04
Longeveron’s CLEAR MIND Randomized Phase 2a Clinical Trial Evaluating Lomecel-B™ in Mild Alzheimer’s Disease Accepted for Featured Research Session Oral Presentation at the 2024 Alzheimer’s Association International Conference (AAIC)	15/04
Top Premarket Gainers	15/04
Longeveron Announces Closing of $5.2 Million Public Offering	11/04
Longeveron Announces Pricing of $5.25 Million Public Offering	08/04
Longeveron Issues Letter to Shareholders Highlighting Corporate Strategy, Clinical Pipeline and 2024 Key Priorities and Goals	08/04
Top Premarket Gainers	08/04
Longeveron to Effect 1-for-10 Reverse Stock Split	20/03
Longeveron Announces 1-for-10 Reverse Stock Split	19/03
Longeveron Reports Year-End 2023 Results and Provides Corporate Update	27/02
Longeveron Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	27/02
Longeveron to Report Year-End 2023 Results and Provide Corporate Update February 27, 2024	21/02
Longeveron Receives Notice of United States Patent Allowance for the Technology Behind its Lead Investigation Product Lomecel-B™	29/01
Longeveron Receives Notice of United States Patent Allowance for the Technology Behind Its Lead Investigation Product Lomecel-B	29/01
Longeveron Closes $2.4 Million Offering	22/12

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Longeveron Inc.

Actions

LGVN

US54303L2034

Autres langues

Filtres